You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid, quantitative and affordable point-of-care diagnostics for oral and oropharyngeal cancer

    SBC: SUMMIT BIOMEDICAL IMAGING LLC            Topic: 102

    Project Summary Abstract This proposal seeks to develop and validate a novel technology for detecting malignant cells in biospecimen samples of oral and oropharyngeal cancerThis technology will allow screeningdiagnosisand quantification at higher precision and lower cost than what is currently availableIn the USboth the incidence and societal impact of oropharyngeal cancer are increasingdespite th ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an a MC1R selective companion diagnostic imaging probe

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Validation of a Platform to Assess and Improve Barriers to Health for Digitally Underserved Populations

    SBC: Responsive Health, Inc.            Topic: 102

    Project SummaryInflammatory bowel diseaseIBDis a chronic disabling disease that leads to poor quality of life among otherwise young healthy adultsUnderserved and minority populations bear a higher disease burden with more hospitalizations and less use of gastroenterology specialty care and of maintenance medications to prevent flaresThe goal of this proposalDevelopment and Validation of a Platform ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. TrachAlarm: A novel, low-cost accessory to automatically detect and alert caregivers to tracheostomy tube decannulation

    SBC: INNOVATIONS UNLIMITED LLC            Topic: NINR

    ABSTRACT The objective of the Phasegrant is to designdevelopand demonstrate feasibility of TrachAlarma novellow cost accessory to automatically detect and alert caregivers when a tracheostomy tube has become accidentally removed from the patientTracheostomy provides a criticallife supporting function for overmillion individuals in the United States with overnew procedures performed each yearEach o ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel recombinant BCG for immunotherapy of bladder cancer

    SBC: MANHATTAN BIOSOLUTIONS, LLC            Topic: 102

    PROJECT SUMMARY Bladder cancer is the sixth most common form of cancer and one of the most deadlyInaloneapproximatelypeople will be diagnosed with bladder cancer in the U Sanddied of the diseasePatients with advanced or metastatic disease have a dismal prognosis and few treatment options after first line chemotherapyMore recentlytherapy with immune checkpoint inhibitor antibodies has shown durable ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. IMPROVEMENT TO OZONATING WATER FOR POST-HARVEST WASHING THROUGH NANOBUBBLES

    SBC: En Solucion Inc            Topic: FDA

    AbstractAs consumer demand for fresh produce continues to growso do concerns by the Food and Drug AdministrationFDAabout foodborne illnesses and foodborne disease outbreaksPostharvest wash is a critical control point in fresh produce processing for reducing or eliminating pathogens and other field acquired contaminants that can result in such outbreaksCurrent methods of post harvest washing typica ...

    SBIR Phase I 2018 Department of Health and Human ServicesFood and Drug Administration
  8. Authentication quantitation and detection of adulteration in botanical dietary supplements using an automated chemometric platform

    SBC: MIDI, INC.            Topic: FDA

    Abstract The objective of this SBIR Phase I proposal is to test the feasibility for development of an automated platform that can perform the followingIdentify botanical components of dietary supplements throughout the supply chain by use of chemicalanalysis and integrated pattern recognition softwareDetect the presence of adulteration by use of HPLCand UHPLCanalysis of bioactive compounds andby u ...

    SBIR Phase I 2018 Department of Health and Human ServicesFood and Drug Administration
  9. Novel SUMO Activators for the Treatment of Duchenne Muscular Dystrophy-Associated Heart Failure

    SBC: SUMOCOR LLC            Topic: NHLBI

    PROJECT SUMMARY Our objective is to develop a small molecule therapy for the treatment of heart disease associated with Duchenne Muscular DystrophyDMDa disease that occurs inout of everymale birthsand for which there is no cure or long term effective treatmentHeart failureHFis a contributing cause of mortality among persons afflicted with DMDA key abnormality in HF is defective handling of calcium ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction

    SBC: VASADE BIOSCIENCES, INC.            Topic: NHLBI

    PROJECT SUMMARY ABSTRACT The most significant advance in the treatment of Myocardial InfarctionMIhas been reperfusion therapywhich must be applied immediately after the MI diagnosis has been madeDespite the thousands of studies on drug therapies designed to reduce the size of the MImost have failed in clinical trialsOur hypothesis is that a major reason why these drugs failed is that they must be ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government